Needham Maintains Buy on Cormedix, Lowers Price Target to $12
Needham analyst Serge Belanger maintains Cormedix (NASDAQ:CRMD) with a Buy and lowers the price target from $20 to $12.
Why Is BIMI International Medical Higher By Around 70%: Here Are 38 Stocks Moving Premarket
Gainers
BIMI International Medical Inc. (NASDAQ: BIMI) shares rose 69.6% to $1.04 in pre-market trading after Fnu Oudom reported a stake of 44% in the company in 13D.
Biotech Investors: August’s Key PDUFA Catalysts You Must Know
Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the month were new molecular entities, underlining a lack of innovation going on in the sector.
73 Biggest Movers From Yesterday
Gainers
AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares jumped 65.9% to close at $2.77 on Monday after gaining around 10% on Friday.
Cormedix: Q1 Earnings Insights
Cormedix (NASDAQ:CRMD) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
Cormedix beat estimated earnings by 18.18%, reporting an EPS of $-0.18 versus an estimate of $-0.22.
Cormedix Q1 EPS $(0.18) Beats $(0.22) Estimate
Cormedix (NASDAQ:CRMD) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.22) by 18.18 percent.
